May 18, 2017 – High-dose oral iron supplements failed to improve peak exercise capacity and had little effect in replacing iron stores in chronic heart failure patients with anemia and reduced left ventricular ejection fraction, states a paper published in the Journal of the American Medical Association.
Iron deficiency – which occurs in around one-half of these patients – is an independent predictor of mortality. Two earlier trials had found that intravenous iron increased exercise capacity and quality of life in this population. The utility of inexpensive, readily available oral iron supplementation in heart failure was unknown.
The JAMA paper reports on the findings from a randomized, double-blind study known as the Oral Iron Repletion effects on Oxygen UpTake in Heart Failure (IRONOUT HF) trial. This investigated the effect of oral iron polysaccharide (150 mg twice daily) compared with matching placebo. Involving 225 patients at 23 U.S. sites between September 2014 and November 2015, IRONOUT HF was an NIH-sponsored multi-center trial.
The JAMA paper concluded that high-dose oral iron minimally repleted iron stores and did not improve exercise capacity in patients with heart failure with reduced left ventricular ejection fraction. The study findings do not support the use of oral iron supplementation to treat iron deficiency in these patients, say the authors.
“We are still trying to find the most straightforward approach to improving the health of patients with chronic heart failure,” said co-author Adrian F. Hernandez, MD, MHS, director of Health Services Outcomes Research at the DCRI. “Unfortunately in this study, we learned that oral iron therapy is not sufficient to improve anemia and ability to exercise in these patients. Intravenous iron supplementation may be more helpful, and is being investigated in a newly-launched large outcomes study called HEART-FID.”
Aimed at enrolling more than 3,000 adult patients across North America, HEART-FID will assess the efficacy and safety of iron therapy using intravenous ferric carboxymaltose, relative to placebo, in the treatment of patients with heart failure, iron deficiency and a reduced ejection fraction. Outcome measures will include the 12-month rate of death, hospitalization for worsening heart failure, and the six-month change in six-minute walk test for patients in heart failure with iron deficiency.
In addition to Hernandez, DCRI and Duke authors of the JAMA paper were Steven McNulty, MS; G. Michael Felker, MD; and Kevin J Anstrom, PhD.
1. Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. Circulation. 2012 Oct 16;126(16):2020–2035.[PubMed]
2. Apple FS. High-sensitivity cardiac troponin for screening large populations of healthy people: is there risk? Clinical chemistry. 2011 Apr;57(4):537–539.[PubMed]
3. Giannitsis E, Katus HA. Highly sensitive troponins knocking at the door of primary prevention. European heart journal. 2014 Feb;35(5):268–270.[PubMed]
4. Sherwood MW, Kristin Newby L. High-sensitivity troponin assays: evidence, indications, and reasonable use. Journal of the American Heart Association. 2014 Feb;3(1):e000403.[PMC free article][PubMed]
5. Saunders JT, Nambi V, de Lemos JA, et al. Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study. Circulation. 2011 Apr 5;123(13):1367–1376.[PMC free article][PubMed]
6. de Lemos JA, Drazner MH, Omland T, et al. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA : the journal of the American Medical Association. 2010 Dec 8;304(22):2503–2512.[PMC free article][PubMed]
7. Eggers KM, Al-Shakarchi J, Berglund L, et al. High-sensitive cardiac troponin T and its relations to cardiovascular risk factors, morbidity, and mortality in elderly men. American heart journal. 2013 Sep;166(3):541–548.[PubMed]
8. Oluleye OW, Folsom AR, Nambi V, Lutsey PL, Ballantyne CM Investigators AS. Troponin T, B-type natriuretic peptide, C-reactive protein, and cause-specific mortality. Annals of epidemiology. 2013 Feb;23(2):66–73.[PMC free article][PubMed]
9. Wang TJ, Wollert KC, Larson MG, et al. Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham Heart Study. Circulation. 2012 Sep 25;126(13):1596–1604.[PMC free article][PubMed]
10. deFilippi CR, de Lemos JA, Christenson RH, et al. Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. JAMA : the journal of the American Medical Association. 2010 Dec 8;304(22):2494–2502.[PMC free article][PubMed]
11. Eggers KM, Venge P, Lindahl B, Lind L. Cardiac troponin I levels measured with a high-sensitive assay increase over time and are strong predictors of mortality in an elderly population. Journal of the American College of Cardiology. 2013 May 7;61(18):1906–1913.[PubMed]
12. Selvin E, Lazo M, Chen Y, et al. Diabetes mellitus, prediabetes, and incidence of subclinical myocardial damage. Circulation. 2014 Oct 14;130(16):1374–1382.[PMC free article][PubMed]
13. Masson S, Anand I, Favero C, et al. Serial measurement of cardiac troponin T using a highly sensitive assay in patients with chronic heart failure: data from 2 large randomized clinical trials. Circulation. 2012 Jan 17;125(2):280–288.[PubMed]
14. Omland T, Rosjo H, Giannitsis E, Agewall S. Troponins in heart failure. Clinica chimica acta; international journal of clinical chemistry. 2015 Mar 30;443:78–84.[PubMed]
15. Borlaug BA, Paulus WJ. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. European heart journal. 2011 Mar;32(6):670–679.[PMC free article][PubMed]
16. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators. Am J Epidemiol. 1989;129(4):687–702.[PubMed]
17. Agarwal SK, Avery CL, Ballantyne CM, et al. Sources of variability in measurements of cardiac troponin T in a community-based sample: the atherosclerosis risk in communities study. Clinical chemistry. 2011 Jun;57(6):891–897.[PMC free article][PubMed]
18. Giannitsis E, Kurz K, Hallermayer K, Jarausch J, Jaffe AS, Katus HA. Analytical validation of a high-sensitivity cardiac troponin T assay. Clinical chemistry. 2010 Feb;56(2):254–261.[PubMed]
19. Parrinello CM, Grams ME, Couper D, et al. Recalibration of blood analytes over 25 years in the atherosclerosis risk in communities study: impact of recalibration on chronic kidney disease prevalence and incidence. Clinical chemistry. 2015 Jul;61(7):938–947.[PMC free article][PubMed]
20. Casale PN, Devereux RB, Alonso DR, Campo E, Kligfield P. Improved sex-specific criteria of left ventricular hypertrophy for clinical and computer interpretation of electrocardiograms: validation with autopsy findings. Circulation. 1987 Mar;75(3):565–572.[PubMed]
21. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern. Med. 2009 May 5;150(9):604–612.[PMC free article][PubMed]
22. White AD, Folsom AR, Chambless LE, et al. Community surveillance of coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) Study: methods and initial two years' experience. Journal of clinical epidemiology. 1996 Feb;49(2):223–233.[PubMed]
23. Rosamond WD, Chang PP, Baggett C, et al. Classification of heart failure in the atherosclerosis risk in communities (ARIC) study: a comparison of diagnostic criteria. Circulation. Heart failure. 2012 Mar 1;5(2):152–159.[PMC free article][PubMed]
24. Heart Failure Society of, A. Lindenfeld J, Albert NM, et al. HFSA 2010 Comprehensive Heart Failure Practice Guideline. Journal of cardiac failure. 2010 Jun;16(6):e1–e194.[PubMed]
25. Kelly JP, Mentz RJ, Mebazaa A, et al. Patient Selection in Heart Failure With Preserved Ejection Fraction Clinical Trials. Journal of the American College of Cardiology. 2015 Apr 28;65(16):1668–1682.[PMC free article][PubMed]
26. Wu AH, Lu QA, Todd J, Moecks J, Wians F. Short- and long-term biological variation in cardiac troponin I measured with a high-sensitivity assay: implications for clinical practice. Clinical chemistry. 2009 Jan;55(1):52–58.[PubMed]
27. Everett BM, Brooks MM, Vlachos HE, et al. Troponin and Cardiac Events in Stable Ischemic Heart Disease and Diabetes. The New England journal of medicine. 2015 Aug 13;373(7):610–620.[PMC free article][PubMed]
28. Harrell FE, Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Statistics in medicine. 1996 Feb 28;15(4):361–387.[PubMed]
29. Pencina MJ, D'Agostino RB, Sr, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Statistics in medicine. 2011 Jan 15;30(1):11–21.[PMC free article][PubMed]
30. Glick D, DeFilippi CR, Christenson R, Gottdiener JS, Seliger SL. Long-term trajectory of two unique cardiac biomarkers and subsequent left ventricular structural pathology and risk of incident heart failure in community-dwelling older adults at low baseline risk. JACC. Heart failure. 2013 Aug;1(4):353–360.[PMC free article][PubMed]
31. White HD, Tonkin A, Simes J, et al. Association of contemporary sensitive troponin I levels at baseline and change at 1 year with long-term coronary events following myocardial infarction or unstable angina: results from the LIPID Study (Long-Term Intervention With Pravastatin in Ischaemic Disease) Journal of the American College of Cardiology. 2014 Feb 4;63(4):345–354.[PubMed]
32. Seliger SL, de Lemos J, Neeland IJ, et al. Older Adults, "Malignant" Left Ventricular Hypertrophy, and Associated Cardiac-Specific Biomarker Phenotypes to Identify the Differential Risk of New-Onset Reduced Versus Preserved Ejection Fraction Heart Failure: CHS (Cardiovascular Health Study) JACC. Heart failure. 2015 Apr 28;[PMC free article][PubMed]
33. Ledwidge M, Gallagher J, Conlon C, et al. Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial. JAMA : the journal of the American Medical Association. 2013 Jul 3;310(1):66–74.[PubMed]
34. O'Meara E, de Denus S, Rouleau JL, Desai A. Circulating biomarkers in patients with heart failure and preserved ejection fraction. Current heart failure reports. 2013 Dec;10(4):350–358.[PubMed]
35. Packer M, McMurray JJ, Desai AS, et al. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation. 2015 Jan 6;131(1):54–61.[PubMed]